FGP
CATX icon

Freestone Grove Partners’s Perspective Therapeutics CATX Stock Holding History

Freestone Grove Partners’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-47,386
Closed -$151K – 608
2024
Q4 		$151K Buy
+47,386
New +$387K ﹤0.01% 547

Other funds holding CATX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $170M AUM 10.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Freestone Grove Partners's CATX Position: Q1 2025 in Review

Freestone Grove Partners sold out of Perspective Therapeutics (CATX) in Q1 2025, closing a stake of 47,386 shares — an estimated $151K sold.

Freestone Grove Partners first reported a position in CATX in Q4 2024 and held it in 1 quarter. The position peaked at $151K in Q4 2024. 112 funds tracked by Wall St. Rank hold CATX as of Q1 2025.

  • Freestone Grove Partners reported no remaining Perspective Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Freestone Grove Partners sold 47,386 Perspective Therapeutics shares in Q1 2025, an estimated $151K.
  • Freestone Grove Partners first reported a position in Perspective Therapeutics in Q4 2024 and held it in 1 quarter.
  • Freestone Grove Partners's Perspective Therapeutics position peaked at $151K in Q4 2024.
  • 112 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2025.

Based on Freestone Grove Partners's 13F filing for Q1 2025, filed 15 May 2025.